Galectin 3 and incident atrial fibrillation in the community

American Heart Journal

Volumn 167, Issue 5, 2014, Pages

  Ho, Jennifer E ^a,b   Yin, Xiaoyan ^a   Levy, Daniel ^a,c   Vasan, Ramachandran S ^a,b   Magnani, Jared W ^a,b   Ellinor, Patrick T ^d   McManus, David D ^a,e   Lubitz, Steven A ^d   Larson, Martin G ^a,f   Benjamin, Emelia J ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GALECTIN 3;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMMUNITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GALECTIN 3; HEART ATRIA; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84899539214     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.02.009     Document Type: Article

References (40)

1. D.M. Lloyd-Jones, M.G. Larson, and E.P. Leip et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study Circulation 106 24 2002 3068 3072
2. J.W. Magnani, M. Rienstra, and H. Lin et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics Circulation 124 18 2011 1982 1993
3. T.J. Wang, M.G. Larson, and D. Levy et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 23 2003 2920 2925
4. D. Li, S. Fareh, and T.K. Leung et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort Circulation 100 1 1999 87 95
5. W.H. Maisel, and L.W. Stevenson Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy Am J Cardiol 91 6A 2003 2D 8D
6. T.H. Everett, and J.E. Olgin Atrial fibrosis and the mechanisms of atrial fibrillation Heart Rhythm 4 3 Suppl 2007 S24 S27
7. S. Nattel, B. Burstein, and D. Dobrev Atrial remodeling and atrial fibrillation: mechanisms and implications Circ Arrhythm Electrophysiol 1 1 2008 62 73
8. R.S. Oakes, T.J. Badger, and E.G. Kholmovski et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation Circulation 119 13 2009 1758 1767
9. A. Goette, T. Staack, and C. Rocken et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation J Am Coll Cardiol 35 6 2000 1669 1677
10. S. Verheule, T. Sato, and T.T. Everett et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1 Circ Res 94 11 2004 1458 1465
11. R.A. de Boer, L. Yu, and D.J. van Veldhuisen Galectin-3 in cardiac remodeling and heart failure Curr Heart Fail Rep 7 1 2010 1 8
12. U.C. Sharma, S. Pokharel, and T.J. van Brakel et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 19 2004 3121 3128
13. L. Calvier, M. Miana, and P. Reboul et al. Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler Thromb Vasc Biol 33 1 2013 67 75
14. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis Proc Natl Acad Sci U S A 103 13 2006 5060 5065
15. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am J Pathol 172 2 2008 288 298
16. J.E. Ho, C. Liu, and A. Lyass et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 14 2012 1249 1256
17. R.V. Shah, A.A. Chen-Tournoux, and M.H. Picard et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
18. R.A. de Boer, D.J. van Veldhuisen, and R.T. Gansevoort et al. The fibrosis marker galectin-3 and outcome in the general population: data from PREVEND J Intern Med 272 2011 55 64
19. W.B. Kannel, M. Feinleib, and P.M. McNamara et al. An investigation of coronary heart disease in families. The Framingham offspring study Am J Epidemiol 110 3 1979 281 290
20. R.H. Christenson, S.H. Duh, and A.H. Wu et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure Clin Biochem 43 7-8 2010 683 690
21. T.J. Wang, M.G. Larson, and D. Levy et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 7 2004 655 663
22. R. Schnabel, M.G. Larson, and J. Dupuis et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection Hypertension 51 6 2008 1651 1657
23. A.S. Levey, J.P. Bosch, and J.B. Lewis et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 1999 461 470
24. P.A. McKee, W.P. Castelli, and P.M. McNamara et al. The natural history of congestive heart failure: the Framingham study N Engl J Med 285 26 1971 1441 1446
25. R.S. Vasan, E.J. Benjamin, and M.G. Larson et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study JAMA 288 10 2002 1252 1259
26. D.J. Sahn, A. DeMaria, and J. Kisslo et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements Circulation 58 6 1978 1072 1083
27. http://www.framinghamheartstudy.org/share/protocols/echo1-6s-protocol. pdf, accessed on 01/21/14.
28. R. Koenker, and G. Bassett Regression quantiles Econometrica 46 1 1978 33 50
29. A. Alonso, B.P. Krijthe, and T. Aspelund et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium J Am Heart Assoc 2 2 2013 e000102
30. S.M. Vaziri, M.G. Larson, and E.J. Benjamin et al. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study Circulation 89 2 1994 724 730
31. M.J. Pencina, R.B. D'Agostino Sr., and R.B. D'Agostino Jr. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2 2008 157 172
32. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 1 2011 11 21
33. B.F. Gage, A.D. Waterman, and W. Shannon et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 22 2001 2864 2870
34. G.Y. Lip, R. Nieuwlaat, and R. Pisters et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2 2010 263 272
35. S. Saba, A.M. Janczewski, and L.C. Baker et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha} Am J Physiol Heart Circ Physiol 289 4 2005 H1456 H1467
36. D.N. Tziakas, G.K. Chalikias, and N. Papanas et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation Europace 9 8 2007 589 596
37. M.F. Swartz, G.W. Fink, and M.F. Sarwar et al. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation J Am Coll Cardiol 60 18 2012 1799 1806
38. Y. Okumura, I. Watanabe, and T. Nakai et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence J Cardiovasc Electrophysiol 22 9 2011 987 993
39. L. Yu, W.P. Ruifrok, and M. Meissner et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis Circ Heart Fail 6 1 2013 107 117
40. R.B. Schnabel, M.G. Larson, and J.F. Yamamoto et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community Circulation 121 2 2010 200 207